Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab for Joint Structural Damage in Rheumatoid Arthritis
NCT00578305Phase 3Completed
- Sponsor
- Roche
- Start
- Nov 2007
- Primary completion
- Nov 2009
- Modality
- Monoclonal Antibodies
- Countries
- 19
01
Overview
Phase 3, randomised, double-blind trial of rituximab in rheumatoid arthritis (RA) (3 arms), sponsored by Roche. Primary endpoint: Change in Magnetic Resonance Imaging Erosion Score at 24 weeks. Started Nov 2007; status: completed.
02
Drugs
rituximab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT00578305.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00578305.